These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Selective administration of prophylactic octreotide during pancreaticoduodenectomy: a clinical and cost-benefit analysis in low- and high-risk glands. Vanounou T, Pratt WB, Callery MP, Vollmer CM. J Am Coll Surg; 2007 Oct; 205(4):546-57. PubMed ID: 17903728 [Abstract] [Full Text] [Related]
3. Clinical validation of the ISGPF classification and the risk factors of pancreatic fistula formation following duct-to-mucosa pancreaticojejunostomy by one surgeon at a single center. Kim WS, Choi DW, Choi SH, Heo JS, Kim MJ, Song SC, Lee HG, You DD. J Gastrointest Surg; 2011 Dec; 15(12):2187-92. PubMed ID: 21997435 [Abstract] [Full Text] [Related]
10. How do we predict the clinically relevant pancreatic fistula after pancreaticoduodenectomy?--an analysis in 244 consecutive patients. Kawai M, Tani M, Hirono S, Ina S, Miyazawa M, Yamaue H. World J Surg; 2009 Dec; 33(12):2670-8. PubMed ID: 19774410 [Abstract] [Full Text] [Related]
11. A grading system can predict clinical and economic outcomes of pancreatic fistula after pancreaticoduodenectomy: results in 755 consecutive patients. Daskalaki D, Butturini G, Molinari E, Crippa S, Pederzoli P, Bassi C. Langenbecks Arch Surg; 2011 Jan; 396(1):91-8. PubMed ID: 21046413 [Abstract] [Full Text] [Related]
16. Options and limitations in applying the fistula classification by the International Study Group for Pancreatic Fistula. Gebauer F, Kloth K, Tachezy M, Vashist YK, Cataldegirmen G, Izbicki JR, Bockhorn M. Ann Surg; 2012 Jul; 256(1):130-8. PubMed ID: 22504279 [Abstract] [Full Text] [Related]